;

Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update

07/11/2019

  • BT7480 selected as lead immuno-oncology candidate to advance into IND-enabling studies
  • Preclinical data on Bicycle® tumor-targeted immune cell agonists to be presented at SITC Annual Meeting on November 9, 2019
  • Cash was $96.0 million at September 30, 2019, which excludes $6.0 million UK R&D incentive received in Q4 2019
  • Continued to enhance corporate leadership through key appointments to management team and Board of Directors

Bicycle Therapeutics, a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today reported financial results for the third quarter ended September 30, 2019 and discussed recent corporate updates.

Read the full article here.

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;